Acute coronary syndrome (ACS) is commonly known as a heart attack or myocardial infarction. This occurs when the heart muscle doesn't get enough blood flow. Every 40 seconds, someone in the U.S. has a heart attack. Knowing the warning signs and symptoms, as well as having access to blood tests to measure cardiac troponin and to an electrocardiogram (ECG or EKG) are key to an appropriate ACS diagnosis, timely management and intervention.
Around 6.2 million U.S. adults have heart failure. Heart failure is a chronic, progressive condition where the heart muscle can no longer effectively pump blood to meet the body's needs. There are various underlying risk factors and conditions that can lead to heart failure. The availability of a blood test measuring natriuretic peptides allows for early diagnosis of heart failure, leading to improved management and quality of life. Additionally, life-changing medications can be safely increased to the most beneficial doses through monitoring these biomarkers.
An estimated 37.3 million people in the U.S. have diabetes, and 96 million have pre-diabetes. Long-standing uncontrolled blood sugar can cause changes to the blood vessels and heart muscles, eventually putting people at a higher risk for heart failure. The use of the appropriate diagnostic tests can identify early heart failure prior to the onset of symptoms, leading to early intervention that can improve quality of life and prevent disease progression. In July 2022, the American Diabetes Association published a consensus statement in partnership with the American College of Cardiology, recommending that all people with diabetes be tested annually for heart failure regardless of signs or symptoms.
Digital and diagnostic solutions have been essential in treating and improving care for people with cardiometabolic disease, whether early identification or last-minute supporting intervention.
Early detection and treatment are crucial for successfully managing cardiometabolic disease. This allows for personalized treatment, reduced costs and appropriate care for people in need.
As cardiac biomarkers and digital solutions evolve, we are committed to continuing research in cardiometabolic disease to advance early diagnosis and help improve clinical decisions.
